ArticleImmunity2008
The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation.
Article in Immunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 62 citations in OpenAlex.
- A poxvirus model reveals general correlates of antigen presentation and immunogenicity for viral CD8Science advances · 2025Article
- Tapasin-mediated editing of the MHC I immunopeptidome is epitope specific and dependent on peptide off-rate, abundance, and level of tapasin expression.Frontiers in immunology · 2022Article
- Hsp90-mediated regulation of DYRK3 couples stress granule disassembly and growth via mTORC1 signaling.EMBO reports · 2021Article
- Direct Priming of CD8Journal of virology · 2021Article
- Kinetically distinct processing pathways diversify the CD8Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Modified Vaccinia Virus Ankara Can Induce Optimal CD8Journal of virology · 2019Article
- Quantification of epitope abundance reveals the effect of direct and cross-presentation on influenza CTL responses.Nature communications · 2019Article
- Increasing antigen presentation on HSV-1-infected cells increases lesion size but does not alter neural infection or latency.The Journal of general virology · 2018Article
- A Mechanistic Model for Predicting Cell Surface Presentation of Competing Peptides by MHC Class I Molecules.Frontiers in immunology · 2018Article
- Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Variable processing and cross-presentation of HIV by dendritic cells and macrophages shapes CTL immunodominance and immune escape.PLoS pathogens · 2015Article
- Immunogenicity of necrotic cell death.Cellular and molecular life sciences : CMLS · 2015Review
- Prolonged antigen presentation following an acute virus infection requires direct and then cross-presentation.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Peptidases released by necrotic cells control CD8+ T cell cross-priming.The Journal of clinical investigation · 2013Article
- Mixed proteasomes function to increase viral peptide diversity and broaden antiviral CD8+ T cell responses.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.Current molecular medicine · 2012Review
- Primary sterile necrotic cells fail to cross-prime CD8(+) T cells.Oncoimmunology · 2012Article
- MHC class I antigen processing distinguishes endogenous antigens based on their translation from cellular vs. viral mRNA.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides.Journal of proteome research · 2012Article
- An invariant road to cross-presentation.Nature immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 4 countries.
Funding
Abstract
The nature of crosspriming immunogens for CD8(+) T cell responses is highly controversial. By using a panel of T cell receptor-like antibodies specific for viral peptides bound to mouse D(b) major histocompatibility complex class I molecules, we show that an exceptional peptide (PA(224-233)) expressed as a viral minigene product formed a sizeable cytosolic pool continuously presented for hours after protein synthesis was inhibited. PA(224-233) pool formation required active cytosolic heat-shock protein 90 but not ER g96 and uniquely enabled crosspriming by this peptide. These findings demonstrate that exceptional class I binding oligopeptides that escape proteolytic degradation are potent crosspriming agents. Thus, the feeble immunogenicity of natural proteasome products in crosspriming can be attributed to their evanescence in donor cells and not an absolute inability of cytosolic oligopeptides to be transferred to and presented by professional antigen-presenting cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.